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ABSTRACT
THE EFFECTS OF DRUGS ON EXPERIMENTAL HEPATIC CAPILLARIA3IS IN MICE
CIIEETBAM, Rosalind Frances* M.Sc.; University of the 
Witwatersrand, 1984.
In this study fourteen anthelmintic compounds were tested in white 
mice for their action against Capillaria hepatica (Nematoda). 
Micej inoculated with 150 embryonated C. hepatica ova, were dosed 
with the drugs on days fourteen to eighteen post inoculation. The 
mice were sacrificed on day twenty-eight of the experiment* The 
livers, where the C. hepatica ova are deposited, were deep-frozen 
at -7Q°C to kill the eggs, and the number of eggs per gram of 
liver was subsequently determined by means of the McMaster chamber 
counting technique.
Of the anthelmintics tested, four prevented the deposition of 
G» hepatica ova in mouse liver at low dose-level^. These were: 
albendazole, 30.0 mg/kg; febantel, 30.0 mg/kg; mebendazole, 
3.13 mg/kgj and oxfendazole, 12.5 mg/kg. Of these, mebendazole is 
the only ons at present marketed locally for human use, and the 
total dose administered is within the recommended dose range.
Scanning electron microscopy was used to study the effects of 
these drugs on C. hepatica worms.
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Capillaria hepatica (Bancroft) 1893) Travossos, 1915 is 
synonymic with both frichocephalus hepaticus and Hepafcicola
' t m r t HMHmww ifw u y  ,«ti> n »».»g« .-r*B'« ai«n»HM «m t i  rrm mmu m tm **:*.......w ih h i t.ipw*  •*•■■■■«>»
hepatica* It is in the same family as the well known 
whipworm Trichuris triehiura. The classification of 
C. hepatica is as follows (Chitwood and Chitwood, 1974)
Phylum 
Class 
Order 
Suborder 
Superfamily 
Family 
Subfamily 
Genus
Species .
C< hepatica is parasitic in the liver of a wide range of 
animals, including rats, mice, dogs, muskrats, beavers, 
rabbits, peccaries, tnonkeys, squirrels, pigs and cats 
(Baylis, 1931; Luttemoser, 1938b; Faust, 1949). It is 
cosmopolitan in its distribution and there are several 
reports of C. hepatica from mammals in the Republic of South 
Africa and elsewhere in Africa, The infection rate varies 
but it is undoubtedly highest in rodents,, For example, Shorb 
(1931) records an infection rate of 48 per cent amongst brown 
rats Ra t* tus norvpf*i eus in Baltimore, United States of 
America. In the same area, Luttermoser (1936) found 
C, hepatica in 86 per cent of adult R. norvegicus and 22 per 
cent of juveniles, Cochrane _et_ a_U (1957) recorded the 
parasite in 28 per cent of a random group of rats caught in 
the vicinity of Johannesburg, Republic of South Africa, 
Waddell (1969) found 79 per cent of a group of R. norvoglcus 
from Brisbane, Australia to be infected with C. hepatica. 
More recently a survey in Connecticut, United States of
Neroatoda
Aphasmidia
Snoplida
Dorylaimina
’frichuroirica
Trichuridae
Caplllarinae
Capillar!a
Capillaria hepatica
America by Conlogue ct al. (1979), revealed that 81 per cent 
of the R. norvogicus rats examined were parasitised by C. 
hepatica, Amongst other host species the infection rate 
would appear to be lower. For example, Wright (1930) records 
G, hepatica infestation in only one per cent of the dogs he 
examined and McQuown (1954) reported it from 4 per cent of 
squirrels trapped in Louisiana, United States of America.
The Li fo Cycle of C. hepatica, including Comment on Spurious 
Infections
The life cycle of C. hepatica is summarised in Figure 1. The 
adult worms are found in the liver, where the females lay 
their eggs. 0. hepatica worms are of typical trichurid 
appearance, having a thicker posterior portion containing the 
intestine and reproductive organs, and a whip-like anterior 
portion containing the stichosome, oesophagus and bacillary 
bands. According to Neafie _et_ al. '1976) there is 
considerable variation in body size of the females, their 
length varying from 52 ram to 104 mm and width from 78^pn to 
184 jim. Males are reported to be more uniform in size, 
namely in the region of 22 mm long (Neafie _et al,* 1976). 
However, Luttermoser (1938b) states that he found males which
and ?8^im in
width. It must be stated, however, that it is extremely 
difficult to measure the length of C. hepatica worms as the/ 
lie tightly coiled within the- livei- tissue and are very 
difficult to dissect out.
After mating, the female worms produce many thousands of 
eggs. These are not excreted from the host’s body but remain 
within the liver until the animal dies and the eggs are 
released into the soil as a result of decomposition. 
Alternatively, if the host is eaten, the eggs pass unaltered 
and unharmed through the digestive tract, to be excreted with 
the faeces (Shorb, 1931). A good example of the latter 
method of egg release is cannibalism amongst rats, which is
measured up to 37 tnm xn length and between 26^im
Larvae, mature, 
mate and lay eggs
Adult worms and eggs 
in liver of mammalian 
host, e.g. rat
V
Host eaten by 
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V
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Embryonated eggs 
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FIGURE I Life Cycle of C. hepatica
thought to account for the high prevalence of this parasite 
within rat populations (Calle, 1961; Farhang-Azad, 1977). It 
is also possible for humans to ingest unombryonated ova of G . 
hepatica, for example, by eating the liver of infected wild 
game (Brosius et al, 1948; McQuown, 1950). The occurrence of 
C. hepatica eggs within the host as a result is teamed a 
spurious infection and, although it may cause transient 
symptoms of pain and diarrhoea, it is not a long-term 
infection of the liver. It is probable that the prevalence 
of such spurious infections is greater than presently 
thought, because of the similarity between the eggs of C» 
hepatica and T> trichiura (McQuown, 1950). Both these 
species have the same basic nematode eggshell structure, that 
is, there is an outer vitelline layer, a middle chitinous 
layer and an inner lipid layer. In C» hepatica, the inner 
portion of the chitinous layer is helicoidal whilst the outer 
portion forms a "pillar and beam-like" network which is not 
present in T. trichiura (Grigonis and Solurnon, 1976; Warton, 
1980). This unusual structure in the chitinous layer of the 
ova of G. hepatica serves to give the outer layer, of what 
appears to be a double shell, a striated appearance not seen 
in T. trichiura. The shape of the eggs of C. hepatica 
an<* T y  trichiura are similar but closer inspection reveals 
that while both ova are elliptical, those of C. hepatica are 
larger, measuring 54 j m  to 65 jim by 29 ^im to 33 jam ' » 
that 49 jam to 54 jim by 21 jam to 23 j m  as in T. trichiura. 
The ova of both species have polar plugs but 
whereas in C. hepatica they do not protrude beyond the outer 
shell layer (see Figures 2a, 2b, 2c and 2d), they do in 
T. trichiura. It should also be noted that the C. hepatica 
ova are passed in the faeces wlu-n in the morula or immature 
two-cell stage. T. trichiura ova, on the other hand, are 
always passed while still unsegmented (Calle* 1961).
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FIGURE 2a Light Micrograph of Sectional G. hepatica Eggs in
House Liver (x 400)
(P - Polar Plug, C - Chitinous layer)
(x 1 000)
(P - Position of Polar Plug)
\PIGURE 2c  Scanning Electron Micrpjn^p h ^ ^ ^
(x 2 000)
(p - Position of Polar Plug)
FIGURE 2d Scanning: F.lectrow Hicroaraph o£ C y Hp.p^j££jEgRS. 
Polar Plug RepiimL. (x 10 000)
(P - Position of: Polar Plug,)
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Taking account o£ the above features, differentiation between 
the ova of these two helminth species should be 
straightforward.
Once free in the soil, the eggs must embryonate before they 
are infective. The factors which determine the rate of 
embryouation are oxygen and moisture availability and the 
ambient temperature, As early as 1931, Shotb experimented 
with embryonating C . hepatica ova at temperatures of 22°Cj 
30°G and 37.5°C for periods of twenty-five and forty-two 
days. His results indicated that although many of the ova at 
37.5°G had embryonaled by day twenty-five, most had 
degenerated by day forty-two. Those at 22°C and 30°G, 
although slower to embryonate, did not degenerate. Wright 
(1961) confirmed these findings, determining the embryonation 
time at 20°C to 24°C to I : a maximum of eight weeks. He also 
found that embryonation did not occur in eggs which had been 
previously subjected to a temperature of -40°C for a period 
of twenty-two hours.
Embryonated ova, when ingested by a new host, hatch in the 
intestine and penetrate the intestinal mucosa from six hours 
after hatching (Luttermoaer, 1938b). The larvae enter the 
hepatic portal vein and are carried to the liver. Wright 
(1961) studied the development of C. hepatica larvae and 
found that second stage larvae were present in the liver 
three to seven days after infection, that third stage larvae 
were apparent from day five and that fourth stage larvae were 
present from day nine. The male larvae matured faster than 
the females, being considered fully developed at day 
eighteen, but females were not mature until two days later* 
Wright (1961) records first seeing female worms bearing eggs 
on day twenty-one, while Luttermoset (I938h) reports seeing 
female worms containing eggs on day eighteen in mice and on 
day twenty-one in rats,
It would appear that animals can withstand very large doses 
of C. hepatica ova, the number of eggs ingested being of more 
critical importance in juveniles. Luttermoser (1938b) found 
that adult mice could withstand doses of 1 000 eggs, although 
the development of the worms was slower than normal and they 
were smaller. Immature mice, however, were killed by doses 
of 500 eggs, Similarly, Luttermoser (1938b) demonstrated 
that a lethal dose in juvenile rats was between 2 500 and 
5 QQ0 ova, whereas adults could tolerate doses of 30 000 ova. 
In animals with massive infections, worms were found free in 
the body cavity, where they appeared to mature normally. In 
addition, worms were infrequently found in the lungs, but 
here the worms lived only eighteen days. Luttermoser (1938b) 
demonstrated that a heavy infestation with C . hepatica caused 
retarded growth of the host, and, especially in mice, 
emaciation. It would appear from his results that in 
rats a small initial infection of C. hepatica "immunised" 
the animal against a larger challenge infection given later. 
Zahner et al. (1980) pursued this idea in some work using the 
multiraammate mouse Mastomys natalensis as the host animal. 
They determined that an initial infection of C. hepatica did 
suppress the reproductivity of a large, but sublethal, 
challenge infection, but if the challenge infection was only 
of moderate size then the existing infection had no effect on 
it.
Normal egg production increases rapidly from about day twenty 
of the infection to a peak at day forty, with no further egg 
production after about day seventy (Lammler et al., 1974). 
After their reproductive functions have been completed, the 
C. hepatica worms die and slowly disintegrate.
91.2 Reasons for Study
The present investigation has been prompted by the fact that 
there are thirteen cases of Q. hopatica infestation in humans 
documented in the literature to date (see Historical Review). 
Three of the cases occured in South Africa. Over half of the 
thirteen cases resulted in death, the infection either having 
been discovered at autopsy*, or, even though the infection was 
diagnosed by liver biopsy, the patient died due to lack of 
suitable treatment.
There is no established cure for C. hepatica infection in 
roan. Some German researchers have looked at the effects of a 
number of drugs on C. hepatica in M, natalensis (Lammler and 
Gruner, 1976), but it was thought that there was scope for 
wore work, in view of the production of new anthelmintics.
" t .  ‘v ^
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2. HISTORICAL RKVTF.W
2.1 Drug Treatment for -Experimental C, hepatica Infection
The first report of experimental chemotherapy of C. hepatica 
infection is given by Wadde.il (1969). He treated rats Rat tug 
rattus subcutaneously and intraperitoneally with three 
200 mg/kg doses of methyridine on days fourteen to sixteen of 
the infection. The results of this study indicated that 
eviposition had been almost totally prevented,
The second study was carried out using the multimammate rat 
Hastomys natalensis (Lammler and Griiner, 1976). Their 
results are summarised in Table 1. These authors examined 
twenty"four compounds for activity against C, hepatica by 
giving five doses, one on each of days fourteen to eighteen 
of the infection, Fenbenda-jole, mebendazole and parbendazole 
were the most effective drugs at low dose levels, as 
indicated by the high percentage reduction in the egg counts 
as compared to the control groups. These three drugs were 
tested further against stage ttfb and stage three larvae - by 
dosing on days five to nine of the, infection. Mebendazole 
and parbendassolc were proved to be most effective.
■*Jk __A __-— v f - W  .UL. f t -
TABLE I Summary of Results of Ltfnunlor and Griiner (1976) for Drug
Treatment of C. hepatica Infect i on.
DRUG DOSE 
mg/lcg x 5*
— —------
% REDUCTION 
IN EGG COUNTS 1
Bitoecanate p . o .  ^ 20 0
40 0
Cambenda^ole p . o . 1.56 0
3.12 56.2
6.25 99.0
12.5 98.6
25 100
50 100
100 100
Diethylcarbaiuazine p . o , 200 0
400 32.3
Disophenol s .c. $ 10 0
20 0
Dithiazanine p ,o . 40 9.4
Fenbcndazole. p.o. 1.56 0
3.12 33.8
6.25 93.6
12.5 99.5
25 100
50 99.9
100 100
Fentln'one p.o. 20 17.0
HOE 28637a p.o. 200 1.7
400 0
HOE 33258d s.c. 2.5 0
5 31.1
10 83.3
20 99.8
20 100
40 100
Hycanthone s.c. 10 19.1
Levamisole p.o. 10 0
15 43.6
20 98.8
40 99,3
TABLE 1 (Continued)
DRUG DOSE % REDUCTION
mg/kg x 51 IN EGG COUNTS1
Mebendazole p.o, 0.78 0
1.56 35.2
3*12 89.5
6.25 99.98
12.5 100
25 100
100 100
Methyridine s*c. 50 0
100 0
200 84.2
400 100
... ~ -..lT1........... .......... .............. ............... .............
Metrifonate p.o, 200
m n n r . r m . M M W  inn . rr , , , ^
15*1
400 33.5
Morantel Tartrate p.o* 200 0
400 0
Niridazole p,o» 100 0
Nitrofurantoins p.o* 100 14.9
Nitroxynil s.c. 5 5*3
'0 58,9
;o 62*: i
k 0 12,6 ]
Parbenda?.ole p.o. 1 . %
3*32 13.9
6.25 56*1
12.3 83*9
25 98.2
50 99*6
100 100
200 r o
Fiperazine Citrate p.o. 250 0
500 0
Pyrantel Tartrate p.o. 100 0
200 0
Suramine s.c. 20 0
40 43.3
Tetramisole p,o« 20 0
30 95.3
40 99*7
TABLE 1 (Continued)
DRUG ' DOSE 
mg/kg x 5-*-
% REDUCTION 
IN EGG COUNTS1
Thiabendazole p.o. 12.5 0
25 61.7
50 34.4
100 77.5
200 87,2
300 98.1
400 99.95
500 99.97
1 See text
2 p»o, per rrnlis
3 s.c. subcutaneous
Review of True Human Infections with C. hepatica
The first report of a ttue case of C . hepatica infection in 
man was recorded by Dive et al, (1924)* The case was that of 
a twenty-year-old man who had been serving in the array in 
India. He exhibited the symptoms of septic pneumonia, and 
after his death the autopsy revealed abcesses in the lungs 
and the liver. Microscopic examination of tissue in 
thevicinity o F the liver abcess revealed masses of eggs which 
were identified as Kepaticola hepatica (a synonym for 
C. hepatica). Material from the periphery of the liver 
lesion revealed mature female, worms. Ho such eggs or worms 
were recovered from the l*ing tissue. It was concluded that 
pyaemia, resulting from the nematode infection and the 
secondary lung infection, was the cause of death.
The next description of a true human infection of C. hepatica 
was given by McQuown (1950) after a girl aged seventeen 
months had been admitted to hospital in Louisiana in the 
United States of America, thought to be suffering from 
pneumonitis and possibly meningitis. When she was first seen 
as an outpatient t/he was suffering from a nasal infection, 
cough and dyspnoea with a raised temperature. She was 
treated with sulfadiazine but three days later she was
admitted to hospital acutely ill, apathetic, stuporous and 
with a grunting respiration. Her liver was enlarged. The 
patient was placed on routine critically ill care but died 
twenty-six hours after admission. At potft-mortem the heart, 
lungs, spleen, kidneys and liver were seen to be enlarged. 
The appearance of the liver was abnormal, being yellowish- 
brown. When cut, the liver proved to be soft with numerous 
small haemarrhagie areas and greyish-tan areas 1 mm to 3 mm 
in diameter scattered throughout the parenchyma and 
resembling small focal areas of necrosis or abceases. 
Microscopically, the liver was found to contain numerous 
granulomas filled with C. hepatica ova and located in the 
periportal spaces. The surrounding chronic inflammatory 
reaction encroached on, and in some places, destroyed, the 
liver lobules. No adult parasites were seen. The lungs did 
not contain parasites. Ascaris lumbricoides nematodes were 
found in the intestine. The final pathological 
diagnosasware; C. hepatica infection of the liver, pulmonary 
oedema, interstitial pneumonitis, acute cardiac dilation with 
congestive failure, malnutrition, dehydration and ascariasis.
Otto et_ al. (1954) documented the case of a seven-year-old 
girl whose C. hepatica infection was diagnosed b'» liver 
biopsy, but who subsequently died. This girl suffered from 
sickle-cell anaemia and had been admitted three times 
previously for sickle-cell crises, before being a d m u e d  to 
hospital in Maryland in the United States of America in 1951 
with fever, shortness of breath and nose bleeds of six days 
duration. In addition to these symptoms, anorexia, lethargy 
and severe malaise were, evident after admission and she 
vomited clotted hlood. She. later developed headaches and 
epigastric, scapular and neck pains. The liver and spleen 
were found to be enlarged. On the forty-sixth hospital day a 
laparotomy was performed. The spleen x*as seen to be twice 
its normal size and the liver was enormous. The liver 
surface was smooth with purplish and white speckles but 
without gross scarring. A liver biopsy and lymph node were
taken. Grossly, the liver revealed tiny yellow foci 1 nun in 
diameter scattered evenly throughout. Microscopically, it 
could be seen that the normal liver architecture had been 
completely disrupted by the parasitic infection. Adult 
worms, often containing eggs within their body cavities, were 
usually at the centre of the necrotic foci, which were 
surrounded by an intense inflammatory response. It was 
thought that these lesions were probably located in the 
portal areas3 but because of the disruption of the liver 
structure j the authors could riot be certain. Eggs were 
present in the liver but no embryonated eggs were seen, which 
is characteristic of G. hepatica infection. The treatment of 
this patient was largely supportive and initially consisted 
of administration of vitamin D and calcium, The liver 
remained enlarged and two courses of chloroquine were given. 
Chloroquine was chosen because its hepatotoxicity is low; 
and it is known to be heavily deposited in the liver and is 
active against some helminths. This treatment was completed 
on the 107th hospital day but the liver continued to enlarge 
and on day 168 a second liver biopsy was performed. This 
second biopsy revealed tiny grey foci which were seen to be 
broad areas of scarring containing enormous numbers of eggs. 
Again the eggs were thought to be, concentrated in the portal 
areas. The liver remained enlarged and the patient was 
discharged on day 203, to be readmitted twice more (orv days 
307 and 331 after the initial admission), in an unchanged 
condition. Nearly two years after the onset of the illness 
the patient was chronically ill and was readmitted for 
weakness, nosebleeds and anorexia. No treatment was given 
and two mont! 9 later she was admitted to hospital with acute 
fever, She developed convulsions and suffered respiratory 
arrest and died five minutes after admission. At autopsy the 
heart, thymus, spleen and kidneys were enlarged, the liver 
being grossly enlarged at nearly four times Khe normal 
weight. Histological examination of the liver supported the 
previous observations which identified the parasite as 
C. hepatica. The authors state that one lung section showed
possible evidence of C. hepatica infection in the form of 
hyaline and calcified bodies in giant cells, although no 
actual eggs or worms were seen. The final diagnosis in this 
patient was C, hepatica infection of the liver with 
granulomatous lesions containing eggs and worms, cirrhosis of 
the liver, ascites, granulomatous lesion of the lung with a 
foreign body reaction, a history of sickle cell anaemia with 
repeated crises, sickle cell lesion of the spleen with 
splenemegaly, marked intravascular sickling of red cells, 
foci of enc eph aIema1ac i a , brain, cardiac hypertrophy and 
dilatation; possible rheumatic myocarditis with Aschoff body 
formation; renal hypertrophy with glomerular engorgement, 
slight focal calcification of renal tubular ephithelium. In 
the final analysis it was admitted that the sickle cell 
disease contributed to the child’s illness and hepatic 
dysfunction, The hepatic disruption was, however, wholly 
attributed to G< hepatica, but hepatic damage, known to occur 
in sickle cell anaemia, may have further aggrevated the 
symtoms of hepatic insufficiency,
Turhan et al. (1954) published the fourth case of true 
C. hepatica infection. In this instance, C, hepatica was 
found incidentally at autopsy in a sixty-year-old man. Thf 
clinical findings were bronchopneumonia and senile dementia, 
and the pathological findings were bronchopneumonia and 
C, hepatica in the liver.
The fifth case of true human infestation with G. hepatica was 
diagnosed in Honolulu and reported by Ewing and Tilden 
(1956). This was the case of a fifteen-month-old female 
infant who was first seen by a physician because of fever, 
anorexia, cough, constipation and a reluctance, to walk. The 
parents stated that their daughter had been known to eat 
dirt. An ascarid infection was diagnosed and treated with 
two courses of hexylresorcinal, which in turn required 
Benadryl ©  (diphenhydramine HCL) to treat the side effects. 
Terramycin ®  (oxytetracycline) was prescribed for the fever
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but upon failing to respond to this treatment, and also in 
view of the pulmonary congestion, the child was hospitalised. 
Fourteen days after the patient was first examined a course 
of Atabrine ©  (quinacrine) was administered. At about the 
same time the liver and spleen were found to be enlarged* 
Shortly after this a course of Hetrassan ©  
(diethylcarhamazine), an effective treatment against 
ascariasis and filariasis, was given together w,, Lederplex 
®  , a brand of vitamin B complex. Nearly one month after the 
girl was first examined a liver biopsy was performed. The 
liver was seen to be greatly enlarged and the surface was 
studded with pearly white granulomatous lesions up to 2 mm in 
diameter. Microscopically, the liver showed massive 
deposition of ova in the portal areas together with many 
worms, and an associated inflammatory reaction. The parasite 
was identified as G. hepatica. The patient w s  discharged, 
although the liver and spleen were still enlarged. Three 
months after the initial examination, the patient was 
readmitted to hospital with bronchopneumonia, cough and 
dyspnoea. The liver and spleen were further enlarged. 
Treatment consisted of continous oxygen, penicillin and 
streptomycin, blood transfusion, intravenous and subcutaneous 
fluids and parenteral vitamins. However, the child died a 
week later. At necropsy the spleen was enlarged and the 
liver greatly enlarged, microscopical examination of the 
liver revealing the ova previously identified as 
C , hepatica. However, the worms had by now degenerated. 
There was considerable liver cell destruction towards the 
periphery of the lobules and the resultant fibrosis had 
distorted the normal liver architecture considerably. 
Microscopic examination of both the lungs and kidneys 
itvealed calcified material, which it was thought provided 
presumptive evidence of 0. hepatica. parasitism in these 
organs, but no eggs or worms were seen.,
Cochrane et al. (3957) provide an account of the sixth case 
of G. hepatica in man to be reported in the world, and the
first case from South Africa. The patient in this instance 
was a fifteen-month-old girl who was reported to be an earth- 
eater. She was admitted to hospital in Vanderbijlpark, 
Transvaal, seriously ill with fever, umbilical hernia, 
enlarged glands and enlarged liver. A liver biopsy was 
performed approximately two months after the onset of the 
child's illness. The liver was found to be moderately 
enlarged and the surface studded with pinhead-sized yellow- 
grey nodules, in places aggregated to form an irregular 
lesion of 2 cm to 3 cm in diameter. The spleen was not 
enlarged. Microscopically, large numbers of ova were seen in 
the portal tracts. The ova were surrounded by areas of 
inflammation, which had resulted in distortion of the liver 
architecture. The parasite was identified as C. hepatica* 
Non-specific drugs which were given included Terramycin ©  
(oxytetracycline), Achromycin ®  (tetracycline with sodiutn- 
metaphosphate), penicillin, Chloromycetin ©  (chloramphenicol), 
Meticorten©(ptadnisone) and Methischol®(choline dihydrogen 
citrate)* As specific therapy against the parasitic 
infection an antimony! drug, Triostam ®  (sodium antimonyI 
gluconate), was given. This controlled the temperature and 
the liver enlargement decreased, Approximately two~and-a- 
half years after the first liver biopsy, a second one was 
performed. The liver size and surface were deemed normal. 
No ova were seen on microscopic examination, although some 
periportal fibrosis was present. The haematological findings 
were also normal. Neatly four years after this child was 
first examined Cochrane and Skins tad (1960) published a 
follow-up report.
The seventh published case of human infestation with 
C, hepatica (Ward and DGtit, 1959) describes the illness of a 
two-year-*old girl. Her case history had included diarrhoea; 
and stool examination had revealed ova of A. lumbricoides and 
T. trichiura, for which infections she. was treated, However, 
the diarrhoea persisted and she developed cough, fevei and 
nausea with vomiting. Prior to hospital admission she had a
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convulsion,, On admission to hospital in New Orleans ir. the 
United States of America, she was lethargic, dehydrated and 
suffered from dyspnoea. The patient was treated with 
intravenous fluids, antibiotics, antipyretics and sedatives. 
About eight hours after admission she expired, having 
received treatment for respiratory distress. The clinical 
diagnoses were bronchopneumonia, intestinal parasitism and 
gastroenteritis due to Shigella sonnei, with anaemia and 
dehydration. Autopsy revealed that the colon was infected 
with T. trichiura and that the lungs and liver were enlarged. 
The liver was tan irt colour and, when cut, tiny scattered 
foci of greyish-tan discolouration about 1 mm in diameter 
were. seen. Kictoscopically these proved to be fibrous 
granulomas enclosing numerous ova of C. hepatica in the 
periportal areas. Microscopic examination of the lungs did 
not reveal any parasites or gram; iomata. Additional 
diagnoses of interstitial pneumonitis and 0. hepatica 
infection of the liver were then made. The authors believe 
that the C . hepatica infection was an incidental finding and 
that death was due to bronchopneumonia and gastroenteritis, 
although, it would seem reasonable to assume that the 
debilitating effect of C. hepatica infection must have 
contributed to the patient's death.
Calle (1961) describes the eighth genuine case of human 
infection with C, hepatica. The patient was a twenty-month- 
old male infant who was admitted to hospital in North 
Carolina in the United States of America, with fever, 
lethargy and abdominal swelling. He was known to 'm, a dirt 
eater. He was treated for sore throat and infected ears but 
there was no reduction in the fever. On the' seventeenth 
hospital day a liver biopsy was done. The liver was seen to 
be purple-tinted, indurated and mottled, with numerous grey 
scars scattered throughout tlve organ. Microscopic 
examination of the scars revealed that they were granulomata 
situated in the portal areas of the liver and containing 
C. hepatica ova. These granulomata were surrounded by an
inflammatory response which had caused partial disruption of 
the liver architecture, Partially disintegrated worm 
fragments were seen but there was no calcification. The 
infection was treated with Delvex (§) (dithiazanine iodide). 
The patient improved and the liver became smaller. Although 
liver biopsy was not performed again, the child appeared to 
be in good health ten months after the initial illness.
The ninth case report is also the second in South Africa. 
Kallichurum and Blsdon-Dew (1961) describe the case of a 
five-year-old girl who was admitted to hospital in Dnrban, 
Natal, with measles, bronchopneumonia and dysentry. Stool 
examination revealed T, trichiura, Trichomonas hominis and 
A. lumbricoides. There was apparently no clinical evidence 
of liver disease and no blood count was done* The patient 
died on the sixth day. At autopsy the liver was seen to be 
of normal size bxxt studded throughout with gtitty yellow- 
white specks 1 tran to 2 mm in diameter. Microscopically these 
appeared as foci of fibrosis and inflammation containing 
numerous ova of C> hepatica, but the surrounding liver 
architecture did not appear distorted.
Romero Garcia et al. (1962) provide the tenth report of human 
infestation with C, hepatica. The case is chat of a twenty- 
two~month old female child from Guadalajata in Mexico, The 
family's living conditions were fairly primitive and there 
were dogs, cats and chickens close by which often strayed 
into the house. Rats and mice were also pt-esent, The child 
was known to be an earth-eater. For two months prior to 
hospital admission the child's symptoms had included fever, 
sweating, anorexia, vomiting, oedema, pale skin, 
palpitations, severe headaches, irritability, and loss of 
weight. Immediately prior to admission the mother had 
detected abdominal swelling and a mass in the abdomen. At a 
previous hospital, blood tests had been carried out and 
leukaemia diagnosed, Upon admission, for the second time to 
hospital, the general clinical picture was as already
described, and, additionally, the liver was found to be 
enlarged and painful to the touch. Blood tests and liver 
function tests revealed leucocytosis, eosinophilia and 
bypergammaglobulinaemia. Several intestinal parasites were 
found. These findings did not confirm the dir^nosis of 
leukaemia. Hetrazon ($) (diethylcarbanmine) was administered 
to deal with the parasitic infections and a steroid was also 
given in varying doses, from 2 mg to 15 mg per day. The 
steroid resulted in the fever disappearing and the 
hepatomegaly, eosinophilia and leucocytosis being reduced. 
If the steroid therapy was suspended the fever returned and 
the patient's general condition deteriorated. Twelve months 
after initiation of treatment, the steroid administration was 
stopped with no ill-effects. At this time a liver biopsy, by 
means of a laparotomy, was performed. The liver was seen to 
be enlarged, with many whitish-yellow nodules of 1 mm to 2 mm 
diameter scattered over the whole surface of the organ. 
Histology revealed numerous granulomata in the portal spaces. 
The granulomata contained eggs of C. hepatica. Fibrotic 
areas were present. There was no infiltration in the lungs. 
The patient was thus diagnosed as having an infection with 
G. hepatica. No further treatment for the infection was 
given.
Details of a case of human G. hepatica infection in Italy 
were published by Cislaghi and Radice (1970), A forty-month" 
old girl who had been ill intermittently for about two ye<u*s 
was admitted to hospital, chronically ill. The major finding 
waa liver enlargement and a liver biopsy was performed. The 
liver appeared cirrhotic with numerous grey scars scattered 
throughout the organ. Microscopically these areas were seen 
to be granulomafca cont,nixing ova of 0. hepatica, which were 
partially calcified. There was an inflammatory response but 
no adult worms were seen, The treatment is not detailed 
beyond the use of unspecified anthelmintic drugs, but the 
patient appears to have survived,
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Silverman at_ ajL (1973) give ar account of the infestation of 
a seventeen-month-old infant girl from Bethal in the 
Transvaal. This constitutes the twelth case in the world 
literature and the third in South Africa, The child was 
admitted to hospital after suffering from cough and fever for 
a month. She was known to be a sand-eater. The liver and 
spleen were enlarged and percutaneous liver biopsies were 
taken. Histological examination showed numerous granulomata 
surrounded by inflammation and containing ova which were 
identified as C. hepatica. Apart from these features the 
liver parenchyma appeared normal. Treatment proceeded wi»'h 
oral iron for anaemia, and Hetrazan (§) (diethylcarbamazine) 
against the parasitic infection. As the patient remained 
ill, Triostarn ©  (sodium antimonyI gluconate) was 
administered. This led to a general improvement in health. 
The patient was discharged. Four months later, a repeat 
biopsy revealed reduction of the fibrosis but ova were still 
present. One year after the initial admission the child was 
still well.
The final and most recent case to be reviewed is from Kaduna 
in Nigeria and is described by Attah et_ al. (1983). A 
tw^nty-seven-year-old woman complained of increased swelling 
in the right side of the abdomen for the previous two years. 
The liver was found to be markedly enlarged. Percutaneous 
liver biopsy revealed extensive fibrosis and inflammation 
surrounding ova Of C. hepatica in the portal areas. There 
was some granulomatous reaction but it was not widespread. 
There was no calcification and no adult worms were seen. 
Treatment with potassium iodide na an outpatient was planned 
but the patient was lost to follow-up, Presumably she. is 
still alive,
The true human cases of C, hepatica infection are summarised 
in Table 2.
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Experimental Animals
>i I ..........H I rl'i' W
All the animals used for experimental purposes were male 
Swiss-Webster White mice obtained from the Central Animal 
Unit at the University of the Witwatersrand, The mice 
usually weighed between 20 g and 33 g at the start of an 
experiment, The mice were housed in groups of five in solid- 
bottomed plastic cages with sawdust as bedding, and fed a 
diet of mouse cubes and water ad libitum. Every experimental 
mouse was given an individual number by means of ear 
punching, using the code shown in Figure 3.
Supply of G. hepatica Eggs
Initially egga of 0. hepatica were obtained by trapping black 
rats Rattus rattua in the vicinity of Johannesburg by means 
of 1 •'rge metal rat traps, killing them with ether and 
examining the liver of each animal for the characteristic 
fibrosis caused by C. hepatica, * When an infected liver was 
found it was processed as in sec ions 3,3 and 3.4 and mice, 
as in section 3*1* were then infected with the parasite, as 
in section 3,6,1, Once the infection had been established in 
the laboratory it was maintained by routine passage in white 
mice,
Separation of Eggs for Embryonation
The infected liver was cut into small pieces and then 
pulverised using a pestle and mortar, in order to break open 
any fibrotic masses containing eggs. The resulting mixture 
was then flushed through a piece of fine gauze material with 
tap~water in order to remove as many large liver particles as 
possible. The filtrate was kept at 4°C and allowed to settle
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(By courtesy of the Department of Toxicology and Reproductive 
Studies, VJyeth Laboratories Ltd., Maidenhead, Berks;., U.K.)
for at least twelve hours. The supernatant was sucked off 
using a venturing pump, leaving the eggs, which sink in 
water, in the sediment at the bottom of the container* The 
container was then refilled with tap~water and replaced at 
4°C. In order to wash the eggs as thoroughly as possible, 
the process of sedimentation and removal of the supernatant 
was repeated several times over a period of approximately 
seven days, until the supernatant was clear.
3.4 Emln*yonation
The clear supernatant of the washed eggs was discarded and 
the eggs, in a minimum of tissue debi'is, were placed in a 
petri dish containing a small amount of tap-water, which had 
been allowed to stand for at least two days. The petri dish 
containing the eggs was then placed for six to eight weeks in 
an incubator maintained at a temperature of between 27°C and 
3G°C (Shorb, 1931; Luttermoser, 1938a; Wright, 1961; 
Vollerthun, et al., 1974; Lammler and GrUner, 1976; Zahner et 
al., 1976). During this time the egg^ were aerated two to 
three times per week by means of a Pasteur pipette and 
dftchlorinated water was added as required, so that the eggs 
did not dry out. After six to eight weeks the percentage 
embryonation was determined by microscopic examination of the 
eggs.
3.5 Egg Counting - for Embryonated Eggs
A modified McMaater counting technique was used (1. >.i*.nr.y of 
Agriculture, Fisheries and Food, 1971; Vollerthun et al., 
1974; Lammler and GrUner, 1976; Dunn, 1978). A known volume 
of eggs in solution was added to zinc chloride solution with 
a specific gravity of approximately 1.6 gcnf^. \ solutioti of 
this nature was obtained by dissolving 1 300 g of zinc 
chloride in one litre of distilled water. The minimum ratio 
of egg suspension to zinc chloride solution had to be 1:14 
(eg. 3 ml. bf egg suspension and 42 ml of zinc chloride
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solution), otherwise it appeared that not all the eggs would 
float. If the concentration of eggs was very high it was 
better to increase the ratio to 1:28, or even more, in order 
to facilitate counting. The zinc chloride/egg suspension 
mixture was thoroughly mixed and a sample rapidly transferred 
to the counting chamber of; a McMaster slide using a Pasteur 
pipette. The eggs were allowed to rise to underneath the 
upper surface of the slide and were then counted 
microscopically. Usually three McMaster chambers were 
counted and an average egg count per chamber used in the 
calculations. The McMaster slide is shown in Figure 4, As 
the counting chamber is ] cm square and 0.15 cm deep, the 
formula for the number of eggs per ml of egg suspension is 
given by;
x (y*z) . 100
y
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where x average egg count
y = size of egg suspension sample in ml 
z - amount of zinc chloride suspension added in ml
Knowing the percentage embryonation of the eggs, as
determined in section 3.4, the number of embryonated eggs per
ml could be calculated. Thereafter, a solution containing
150 eggs in 0,2 ml could be prepared for administration to 
the test animals.
Experimental Design
C, hepatica eggs were administered to the experimental mice 
on day one of the experiment (section 3,6.1) and their body
FIGURE 4 McMasfcer
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weights recorded. On days fourteen to eighteen post 
inoculation the drugs were administered to the mice according 
to their daily body weights (section 3.6.2). On day twenty- 
nine post inoculation each animal was weighed, anaesthetised 
with ether, and then its jugular vein was severed for 
exsanguination so that the liver did not act as a reservoir 
for blood and make the liver weights inconsistent. The body 
cavity was opened up, any gross abnormalities noted, and the 
liver removed and weighed. The livers from each group of 
mice were photographed. Each liver was wrapped individually 
in a plastic bag and labelled with the experiment code, mouse 
number, cage number, drug and dose-level. The mouse livers 
were frozen at -70°G for* a minimum of seventy-two hours in 
order to render the C. hepatica eggs uninfective (Wright, 
1961). The livers were then processed by means of a modified 
liver digestion technique (section 3.6.3). The number of 
eggs pet gram of liver was calculated and the results 
evaluated (sections 3.6.4 and 3*6.5).
Pilot experiments were first performed with each. drug. This 
involved using very high dose-1 evels of the test drug to 
determine whether or not the drug had any potential use 
against C» hepatica. Three dose-levels were used in each 
case, doses at each level being administered to five mice 
from days fourteen to eighteen of the infection, A control 
group of five infected but untreated mice was used, For 
drugs which appeared to bo having an advantageous effect on 
the infection, further experiments were performed using much 
lower dose-levels *
3.6.1 Infection of Test Animals
The test animals were inoculated per os with 
approximately 150 embryonated C. hepatica eggs, by means 
of a blunted metal cannula attached to a 1 ml disposable 
plastic syringe. The dosing syringe is illustrated in
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Figure 5 and the dosing procedure in Figures 6a and 6b, 
Since the eggs sink rapidly in water, care had to be 
taken to shake the bottle containing the eggs before 
filling the syringe, in order to administer the required 
number of eggs as accurately as possible.
3.6*2 Drug Administration
A list of drugs used, the manufacturers and other 
pertinent information is given in Appendix A. Each drug 
came in one of the following forms:
(i) Powder soluble in water
(ii) Powder insoluble in water
(iii) Suspension rniscible with water
(iv) Suspension not rniscible with water
A powder which was insoluble in wafer was suspended in a 
solution of gum tragacanth by means of a homogeniser. A 
suspension not rniscible with water was supplied with a 
suitable fluid for dilution^ which was also used as a 
placebo for the control animals where applicable. The 
drugs were supplied in known concentrations. 
Consequently, the required dose-levels could be prepared 
so that each drug was administered in an amount of 1 ml 
fluid per 100 g body weight. Thus, if the dose-level 
was 500 mg/kg, then each 1 ml of the solution to be 
administered contained 50 mg of the drug. The drugs 
were prepared daily and given to the test animals as in 
section 3.6.1, Drugs were, administered in ascending 
order of concentration and a new syringe was used for 
each drug, the dosing needle having been thoroughly 
washed, Control groups were dosed with distilled water, 
gum tragacanth or placebo, according to which had been 
used for drug administration in the particular 
experiment concerned.
FIGURE 5
FIGURE 5
FIGURE 6a Dosing Procedure ~ I
FIGURE 6b Doainp; Procedure - II
M odified Liver M p.eflfclon Technique
The technique described by Matsusaki (1951) (cited by 
Vollerthun et al., 1974; Lcimmler and Grliner, 1976;
M ttHM  PW«WW>
Zahner et al ., 1976) was modified and used as follows:
A solution containing 0.7 g pepsin, 6 ml normal (molar) 
hydrochloric acid and 94 ml distilled water was placed 
in a 250 ml round-bottomed flask. The liver was cut 
into small pieces and added to the solution, the flask 
being clearly labelled. The flask was held in a water- 
bath maintained at 37,5°C and stirred by means of a 
vibrating stirrer obtained from Chemapec (Pty) Ltd., 
P.O. Box 9051, Johannesburg, South Africa. The 
apparatus is shown in Figure 7. The flask was stirred 
for a minimum of three hours, or until all the fibrotic, 
masses had been broken up. The resulting solution was 
made up »:i 100 ml with distilled water and placed in a 
sealed flask it 4°C unr.il required for examination.
Egg wivuueinp, ~ for Liver Examination1 *■ • 'UKMMMtWOTM ........................................ ,Hllllim*'W W H I uhl'W HHlM WImi*
Thri iiuspe*-»ion was thoroughly mixed and a 3 ml
K-H.juu i re •! wifeh a graduated pipette. 42 ml of 
j .6 g e n f z i n c  chloride solution was added to this 
sample. This solution was thoroughly mixed and a sample 
taken quickly with a Pasteur pipette and run into a 
McMaster counting chamber. Three samples were examined 
microscopically and the eggs counted is described in 
flection 3.5.

The formula for the weight of liver examined per 
McMaater chamber (Wm) is given by;
Wtti * V . 3 . 0,15 
200 . 45
Wm » W , 5 . 10“5
Where I<? weight of the mouse liver in grams.
?i •. : v!lf eggs per gram of liver (EL) is given by;
v; 1,
- m
*. ■»: ■■ ;i\fv;rsgc egg count per McMaM::r chamber.
Tti<; percentage ►'eduction in the number of eggs present
in i;he livci is given by:
(Average EL for givci 
R e d u c t i o n  - 1 0 0  d r u a / d o s e - l e v e l j  . 1 0 0
(Average EL for Control group)
The liver weight per 10 g body weight was calculated for 
each mouse, and the Dunne11* s test, for comparison of 
treatment means with the control, was performed to 
compare liver weights between dosed and control groups 
(Dunnett, 1964),
A linear regression analysis was utilized to investigate 
the relationship between the number of eggs per gram of 
liver and the liver weight.
Scanning Electron Microscopy (SEM)
For drugs which proved to be effective, as determined by 
the egg counts from the low-dose experiments, groups of 
five mice were infected with C. hepatica, as in section 
3,6.1, and treated with drugs, as in section 3.6.2, The 
dose-levels used were the lowest effective dose-levels 
for the appropriate drugs, as determined by the low-dose 
experiments. The mice were killed on day nineteen post 
inoculation by means of ether, A control group of five 
mice was also infected with C. hepatica and dosed with 
distilled water.
Livers were removed and some of the worms extracted by 
tuicrod Is section, Worms were immediately fixed in 
glutaraldehyde at room temperature (to prevent excessive 
shrinkage) for a minimum of one hour. The worms were 
then washed in cacodylate buffer and post-fixed in 
osmium tetroxide at 4°C for at least one hour, or until 
the worms had turned black. The were then washed
in buffer and dehydrated at 4°w t'trough an ascending 
alcohol series. The wox*ms were critical point dried, 
mounted and gold-coated before, examination under the 
scanning electron microscope (after Wrigbt, 1978),
RESULTS
Effects of T)rugs
A summary of the high-dose pilot experiment results is 
given in Table 3 and the control data in Table 4. Full 
experimental data from which these tables are derived 
are given in Appendix B, In ordur for the drug to be 
deemed effective, it was required to cause more than 99 
per cent reduction (against the control) in the number 
of eggs present in the livers of the experimental mice*. 
The column scoring the liver appearance is, admittedly, 
a subjective measurement, but as can be seen from the 
photographs which follow, the liver appearance 
(including apparent fibrosis, colour and texture) is a 
reasonable indication of the degree of infestation with 
G. hepatica. In the pilot experiments, four drugs 
showed the required degree of efficacy, and these were 
then subjected to low-dose trials. They were 
albendozole (Valbazen ©  ), febante'i. (Rintal ($) ), 
mebendaz (Vermox (§) ) and oxfendazole (Systanvex ®  ). 
Also in the case of these drugs, the Dunnett's test to 
determine any significant difference between the control 
and treated liver weights is recorded as being highly 
significant at one per cent, i.e. there is a very 
significant difference between the control and treated 
liver weights, which has not arisen by chance.
The results of the low-dose experiments are. given in 
Table 5 and the control data in Table 6. Full 
experimental data from which these tables are derived is 
given in Appendix C. The lowest dose-level in these 
experiments was chosen so that the total dose 
administered fel] within, or was very near to, the dose- 
levels recommended by tlu manufacturers.
TABLE 3 Results of Pilot Experiments
DRUG NAME
DOSE
mg/kg
X5
NUMBER OF 
MICE TO 
SURVIVE
LIVER
APPEARANCE1
EGGS/ g LIVER DUHNETT* S 
TEST
CONTROL
GROUP
x x 104 % REDUCTION
Albendazole 125 5 + 4- 0.1 99,8 0.01 B
(Valbazen (R)) 250 5 ++ 0.2 99.7 0.01 B
500 5 ++ 0.3 99,6 0.01 B
Amoscanate 125 5 0 163.1 20,2 N.S. El
250 5 0 150.7 26.3 M.S. El
500 2 0 255.8 0 H.5. El
Febantal 62,5 5 ++ 0,1 99.9 0.01 C
(Rintal (R)) 125 5 ++ 0.4 99,8 0.01 C
250 5 •f + 0,2 99.9 0.01 C
Mebendazole P.25 \ ++ 0,1 99.9 0.01 A1
(Vermox(g)) 12.5 5 ++ 0.1 99.9 0,01 At
25 5 ++ 0,1 99.9 0,01 A1
Niclosamide 125 4 0 153.6 9.5 N.S. C
(Lintex (§)) 250 4 0 135.8 20.0 N.S. C
500 5 0 67.5 60.2 N.S. C
Oxantniquine 125 5 0 90.3 0 N.S. fcc
(Yansil (§)) 250 5 0 74.5 1,3 0.01 E2
500 2 0 73.2 3.1 N.S. E2
Oxfendazolfc ' 56.25 5 | + 0 100 0.01 0
(Systaraex (f)) 112.5 5 + 0 100 0.01 0
225 5 + 0 100 0.01 0
Gxyclozanide 85,0 5 0 26.6 65.8 N.S, B
(ICI Liver 170 5 0 40.7 47,6 N.S. B
Fluke Remedy (R)) 340 4 o .... 5.3 93,1 N.S. B
Plperaz-ine 125 5 0 123,7 0 N.S, B
adlfijte 250 5 0 124.3 0 N.S. 8
(.Ascarad'iria^ f); SOO 5 0 175,6 0 0.05 B
Piperaz v<te 125 5 0 196,0 28,4 N.S, A
citrate 250 5 0 110.3 59.7 N.S. A
( R id®) 500 5 0 248.6 9.1 N.S. A
Piperazine 125 2 0 100.0 0 N,S, D
dihydrochloride 250 4 0 133. v 0 N.S. D
(Wazlne (R)) 500 4 0 157.1 0 N.S. D
Praziquantel 50.0 5 0 72,9 73.4 N.S. A
(Droncit (§)) 100 b 0 229.7 16.1 N.S. A
200 0 "* * * A
Pyrantel 125 5 0 66.7 75.6 N.S. A
(Combantrin (R)) 250 5 0 86.5 68.4 N.S. A
500 5 0 117,0 57.3 N.S. A
Rafoxanide 62,5 5 + 66.4 60,9 0,01 C
(Ranlde ® ) 125 3 + 70.1 58.7 0.01 C
250 0 ” C
(Tnnt 1nur*d 1
TABLE 3 (Continued) ..........
* Key To Liver Appearance Symbols
0 : No apparent difference in appearance from the control 
livers.
+ I Some reduction in fibrosis apparent.
++ ; Considerable reduction in fibrosis.
TABLE 4 Results for Pilot Experiment Control Groups
CONTROL GROUP
NUMBER OP 
MICE TO 
SURVIVE
x EGGS/g LIVER 
x 104
A1 5 120.7
A 5 273.7
B 5 77.6
C 5 169,7
1) . 5 87.9
El 5 204.3
E2 5 75,5
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TABLT 5 (Continued) . . . .
Key To Liver Appearance Symbols
No apparent difference, in appearance from the control 
livers.
Some reduction in fibrosis apparent.
Considerable reduction in fibrosis,
0
TABLE 6 Results for Low-Doso Experiment Control Group?.
CONTROL GROUP
NUMBER OF 
MICE TO 
SURVIVE
x EGGS/g LIVER 
X 104
F 5 33.9
H 5 56,8
J 5 66.9
For each drug a trend may be seen, which will be 
described below. In order for the experimental, 
photographs to be assessed objectively, reference should 
be made to Figures 8 and 9 which are photographs of 
livers of uninoculatecl and inoculated control mice, 
respectively. Bearing in mind that the scales are 
different, the uninoeulated mouse livers (Figure 7) are 
dark blood red in colour and are generally smaller than 
the inoculated controls (Figure 8). The inoculated 
control mouse livers are paler, because of the fibrotic 
masses of eggs located within the liver parenchyma. 
These livers are heavier than normal and firm to the 
touch, not soft and easily damaged as is a normal liver.
Albendazole (Valbazen©); Figures ID - 19
The lowest: dose of this drug administered to mice was 
1,88 mg/kg (total dose 9.40 mg/kg). At this level the 
livers closely resembled the. inoculated control livers 
in colour and texture; tbu, Dunne tfc’s test was not 
significant and the egg count was reduced by only 20.5 
per cent. If Figures 10 - 14 (dose-levels from 
,1.88 mg/kg to 30.0 mg/kg) are examined, a progression 
indicating an improvement in the condition of the liver 
may be seen. The fibrosis is gradually reduced untxi at
30.0 mg/kg there are only a few white fibrotic areas 
visible, the livers being predominantly a healthy colour 
and more natural in texture, At 30,1) mg/kg the egg 
burden is reduced by 99.8 per cent and the Dunnett's 
test shows a highly significant difference in weight 
between treated and control livers, Figures 15 - 19 
(dose-levels from 60.0 mg/kg to 500 mg/kg) show livers 
which are almost completely tiealthy, having only a few 
small pockets of fibrosis.
Tg
7+3
4.1.2 Febantel (Rint.il ®  ) ; Figures 2.0 - 29
For this compound the; lowest dost? administered was 1.25 
mg/kg (total dose 6.25 mg/kg). At this level the livers 
were identical to those of the inoculated controls in 
colour, texture and apparent abundant fibrosis. The 
Bunnett's test was not signifant and there was no 
reduction in egg count. If one examines Figures 20 - 25 
(dose-levels from 1.25 rag/kg to 30.0 mg/kg) a similar 
picture of improvement in the liver condition to that 
for albendazole, may be seen. There are no visible 
differences between Figures; 20, 21 and 22 (1.25 mg/kg, 
2.50 mg/kg and 5.00 mg/kg respectively), and in fact 
these livers show no numerical, reduction in the number 
of eggs present. However, at 10.0 mg/kg (Figure 23), 
the fibrosis can be seen to be slightly reduced; and at
15.0 mg/kg and 30,0 mg/kg (Figures 24 and 25) the liver 
is seen to be normal in colour (and normal as regards 
texture), with only a few pale fibrotic areas visible. 
It is at 30.0 mg/kg tb t the egg count is reduced by 
more than 99 per cent. ’!;.<> Durmett's test also reflects 
these changes, from being 5 per cent significant at
10.0 mg/kg to highly significant (one per cent) at
15.0 mg/kg and 30,0 mg/kg. Figures 26 -* 29 (dose-levels 
from 60.0 mg/kg to 250.0 mg/kg) show livers which are 
almost normal. Fibrosis is almost entirely absent at 
the high dose-1evels.
4.1.3 Mebendazole ( V e r m o x ) ; Figures 30 ~ 33
Mebendazole (Vermox ©  ) is the most effective 
anthelmintic against 0. hepatica investigated to date. 
This drug is highly effective against this parasite at 
as little as 3,13 mg/kg (total dose 15.63 mg/kg). 
Figure 30 (3,13 mg/kg) shows normal-coloured livers with 
a few pale fibrotic patches. This picture continues in 
Figures 31 - 33 (dose-levels 6.25 mg/lcg to 25.0 mg/kg).
- Y ' \
-
k  i? ‘
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The Dunnett's to.at also shows the difference in the 
liver weights (as compared to the controls) to be highly 
significant at all the dose-levels used.
4.1.4 Oxfendazole (Sy8tamp* ,(]R) ) ; Figures 34 - 43
The lowest dose of this drug to be administered wag 1.25 
mg/kg (total dose 6.25 mg/kg), Figures 34 ~ 37 (dose- 
levels from 1.25 mg/kg i,o 10.0 mg/kg) reveal livers 
which still have large amounts of fibrosis present» 
although in some livers it is reduced, giving rise to a 
pale, mottled appearance. At dose-leve.ls oC 5,0 mg/kg 
and 10.0 mg/kg there is some reduct if"; in the egg 
counts i although the Dimnett's t<-..~ l remains non­
significant. Between 10,0 mg/kg and 17..5 mg/'ig ^Figures 
37 and 38) there is a dramatic change. At 12.5 mg/kg 
the livers have a more normal blood-red colour and 
fibrosis is greatly reduced. The number of eggs present 
is reduced by 99.8 per cent at 12.5 mg/kgj and the 
Dunned;1 e test shows a highly signif Lei at difference 
between the control and experimental liver ’/‘j.hts. The 
liver appearance continues to improve > the higher 
dose-1 eve Is (Figures 39 ~ 43; dose-le,, ' i.B ire • 25 
mg/kg to 225 mg/kg), reveal ing livers c f normal colour 
and siae, and having only a few pale fibrofic patches.
4.1*5 Other Drugs Tested ; Figures 44 - 53
Figures 44 - 53 show the livers oE mice from the hifbest 
dose groups of all the remaining drugs tested. None of 
these drugs caused any significant reduction in egg 
numbers. The photographs show livers which are similar 
in appearance (and texture) to the inoculated control 
mouse livers shown in Figure 9.
I
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Citrate (Rid ®  )
Scale bar indicates 25 mm }_____ [
# *» 
f_ _* ■AwwwjX.
EXPT 0
MOUSE no 2 U  
CAGE no 34 
SOOmo/xg WfiiiKfc*
expr tf
■MOUSE no 356
CAGE no 35 
'so&raj/ku ivazmtr
EXPT u ■
MOUSE no 215 
CAGE no 34 
.SOOmg/kj v /A tM
■EXPT S)
MOUSii no 217 
CAGE no 35 
SOOfliS/Iiff WASHNE
FIGURE SO Livers from Mice Dosed with 500 mp,/kg Piperaziae
Dihydrochloride (Waaino ®  )
Scale bar indicates 25 mm [- i
Hxpt A MOUftt ft a 
OAO:. no 5 
lOtimff/tij WtCilClT
0
F, *pt A 
MOUSF «d VI 
CAf.i?. 5io 5
ttV' vk«) uRPyCrt
Exp I  A 
MOUSE no 72 
CA&. no 8 
ii)t» hi/*.? cnc?;>'t'f
Expt A 
M'JUSli no 73
i * \ no 8 
100 « ,'kD tB-KlT
Expt A 
MOUSE no 74 
CAGE no S m m m  tsROfjiit
FIGURE 51. Livers from Mice Dosed with 100 mg/kg Praziquantel 
(Droncit (R) )
Scale bai: indicates 25 ram |______j
Author Cheetham R F
Name of thesis The effects of drugs on experimental hepatic capillariasis in mice 1984
PUBLISHER:
University of the Witwatersrand, Johannesburg  
©2013
LEGAL NOTICES:
Copyright Notice: All materials on the U n i v e r s i t y  o f  t he  W i t w a t e r s r a n d ,  J o h a n n e s b u r g  L i b r a r y  website 
are protected by South African copyright law and may not be distributed, transmitted, displayed, or otherwise 
published in any format, without the prior written permission of the copyright owner.
Disclaimer and Terms of Use: Provided that you maintain all copyright and other notices contained therein, you 
may download material (one machine readable copy and one print copy per page) for your personal and/or 
educational non-commercial use only.
The University o f the W itw atersrand, Johannesburg , is not responsible for any errors or omissions and excludes any 
and all liability for any errors in or omissions from the information on the Library website.
